In the News
Successful completion of development of a precision therapeutic system designed to safely achieve high concentration of chemotherapeutic in target organ, via non-circulatory pathways and with little to no systemic drug exposure and associated toxicity. Cary, NC October 25, 2023 —…
RALEIGH, N.C. (November 1, 2022): Focal Medical, Inc. (formerly Advanced Chemotherapy Technologies, Inc.), a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative local drug delivery technology platform, today announced the appointment of Michael Aldridge as the Company’s…
This investment is in addition to the previously announced Series A investment of $5.5 million lead by Khosla Venture. Read More
Tony Voiers joined Advanced Chemotherapy Technologies as CEO after meeting with company co-founder Jen Jen Yeh, a professor of surgery at the UNC School of Medicine. Voiers relies on his experience in engineering and management to run the business, which…
November 18, 2018— Bioscience companies from North Carolina dominated the awards competition at the 20th annual SEBIO Investor and Partnering Forum in Atlanta this month, with nine Tar Heel firms earning recognition. Read More
There are few illnesses as crafty as pancreatic cancer. It spreads like weeds and resists chemotherapy. Pancreatic cancer is often asymptomatic, has a low survival rate and is often misdiagnosed as diabetes. And, this violent killer is almost always inoperable…
Fueled by the passion of pioneering physicists, physicians and medtech innovators looking for a way to fight cancer and make an impact on patient survival and quality of life, cutting-edge oncology devices under development today include an implant designed to…
Pancreatic cancer is an elusive and deadly disease. It often has no initial symptoms, and there are no reliable tests for early detection. The mortality rate is 75 percent within a year of diagnosis, and the five-year survival rate is…
